{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:40:39Z","timestamp":1784673639830,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T00:00:00Z","timestamp":1306195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1038\/bjc.2011.178","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T19:56:40Z","timestamp":1306267000000},"page":"1816-1821","source":"Crossref","is-referenced-by-count":46,"title":["Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens"],"prefix":"10.1038","volume":"104","author":[{"name":"for the Italian Melanoma Intergroup (IMI)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Chiarion-Sileni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Romanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Pigozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Brugnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G L","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,24]]},"reference":[{"issue":"10","key":"BFbjc2011178_CR1","first-page":"3075","volume":"8","author":"MB Atkins","year":"2002","unstructured":"Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW (2002) A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 8 (10): 3075\u20133081","journal-title":"Clin Cancer Res"},{"issue":"7","key":"BFbjc2011178_CR2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (7): 2105\u20132116","journal-title":"J Clin Oncol"},{"issue":"6","key":"BFbjc2011178_CR3","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/annonc\/mdi190","volume":"16","author":"D Bafaloukos","year":"2005","unstructured":"Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H (2005) Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 16(6): 950\u2013957","journal-title":"Ann Oncol"},{"issue":"16","key":"BFbjc2011178_CR4","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (16): 3635\u20133648","journal-title":"J Clin Oncol"},{"issue":"14","key":"BFbjc2011178_CR5","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 (14): 2865\u20132872","journal-title":"J Clin Oncol"},{"issue":"12","key":"BFbjc2011178_CR6","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (12): 2972\u20132977","journal-title":"Cancer"},{"issue":"6","key":"BFbjc2011178_CR7","first-page":"488","volume":"23","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23 (6): 488\u2013496","journal-title":"Oncology (Williston Park)"},{"issue":"7","key":"BFbjc2011178_CR8","first-page":"1629","volume":"5","author":"CD Britten","year":"1999","unstructured":"Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG (1999) A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5 (7): 1629\u20131637","journal-title":"Clin Cancer Res"},{"issue":"9","key":"BFbjc2011178_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/38.9.1974900","volume":"38","author":"C Cordon-Cardo","year":"1990","unstructured":"Cordon-Cardo C, O\u2019Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38 (9): 1277\u20131287","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"BFbjc2011178_CR10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0022-3565(24)39120-7","volume":"294","author":"S D\u2019Atri","year":"2000","unstructured":"D\u2019Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP (2000) Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294 (2): 664\u2013671","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"BFbjc2011178_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","volume":"20","author":"O Eton","year":"2002","unstructured":"Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 (8): 2045\u20132052","journal-title":"J Clin Oncol"},{"issue":"16","key":"BFbjc2011178_CR12","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","volume":"25","author":"ER Gerstner","year":"2007","unstructured":"Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25 (16): 2306\u20132312","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2011178_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/01.cmr.0000195697.58013.b7","volume":"16","author":"M Gonzalez Cao","year":"2006","unstructured":"Gonzalez Cao M, Malvehy J, Marti R, Conill C, Sanchez M, Martin M, Carrera C, Herrero J, Gascon P, Mellado B, Castel T, Puig S (2006) Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma res 16 (1): 59\u201364","journal-title":"Melanoma res"},{"key":"BFbjc2011178_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141\u20131154","journal-title":"Ann Stat"},{"issue":"7","key":"BFbjc2011178_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.6004\/jnccn.2006.0057","volume":"4","author":"AN Houghton","year":"2006","unstructured":"Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ (2006) Melanoma. J Natl Compr Canc Netw 4 (7): 666\u2013684","journal-title":"J Natl Compr Canc Netw"},{"issue":"34","key":"BFbjc2011178_CR16","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","volume":"25","author":"NJ Ives","year":"2007","unstructured":"Ives NJ, Stowe RL, Lorigan P, Wheatley K (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25 (34): 5426\u20135434","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2011178_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (1): 158\u2013166","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2011178_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10147-008-0797-8","volume":"14","author":"M Ono","year":"2009","unstructured":"Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K, Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y (2009) Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 14 (1): 48\u201352","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"BFbjc2011178_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00008390-200204000-00011","volume":"12","author":"MJ Paul","year":"2002","unstructured":"Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma res 12 (2): 175\u2013178","journal-title":"Melanoma res"},{"issue":"3","key":"BFbjc2011178_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1179\/joc.1995.7.3.224","volume":"7","author":"D Piccioni","year":"1995","unstructured":"Piccioni D, D\u2019Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani G (1995) Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 7 (3): 224\u2013229","journal-title":"J Chemother"},{"issue":"5","key":"BFbjc2011178_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/01.coc.0000164006.72694.1b","volume":"28","author":"N Ready","year":"2005","unstructured":"Ready N, Aronson F, Wanebo H, Kennedy T (2005) A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. Am J Clin Oncol 28 (5): 479\u2013484","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"BFbjc2011178_CR22","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.2002.20.6.1600","volume":"20","author":"R Ridolfi","year":"2002","unstructured":"Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20 (6): 1600\u20131607","journal-title":"J Clin Oncol"},{"issue":"4","key":"BFbjc2011178_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/01.cmr.0000136711.75287.55","volume":"14","author":"R Ridolfi","year":"2004","unstructured":"Ridolfi R, Romanini A, Sileni VC, Michiara M, Guida M, Biasco G, Poletti P, Amaducci L, Leoni M, Ravaioli A (2004) Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma res 14 (4): 295\u2013299","journal-title":"Melanoma res"},{"issue":"1","key":"BFbjc2011178_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/01.cmr.0000183921.46031.93","volume":"16","author":"IG Ron","year":"2006","unstructured":"Ron IG, Sarid D, Ryvo L, Sapir EE, Schneebaum S, Metser U, Asna N, Inbar MJ, Safra T (2006) A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma res 16 (1): 65\u201369","journal-title":"Melanoma res"},{"issue":"3","key":"BFbjc2011178_CR25","first-page":"853","volume":"149","author":"K Toth","year":"1996","unstructured":"Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM (1996) MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149 (3): 853\u2013858","journal-title":"Am J Pathol"},{"issue":"35","key":"BFbjc2011178_CR26","doi-asserted-by":"publisher","first-page":"8992","DOI":"10.1200\/JCO.2005.02.5791","volume":"23","author":"RW Weber","year":"2005","unstructured":"Weber RW, O\u2019Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE (2005) Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 23 (35): 8992\u20139000","journal-title":"J Clin Oncol"},{"key":"BFbjc2011178_CR27","first-page":"2655","volume-title":"Cancer: Principles & Practice of Oncology","author":"PY Wen","year":"2001","unstructured":"Wen PY, Black PM, Loeffler JS (2001) Treatment of metastatic cancer. In Cancer: Principles & Practice of Oncology DeVita Jr VT, Hellman S, Rosenberg SA (eds) 6th edn, pp 2655\u20132670. Lippincott, Williams & Wilkins: Philadelphia, PA"},{"issue":"2","key":"BFbjc2011178_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/CMR.0b013e3283350578","volume":"20","author":"E Wierzbicka-Hainaut","year":"2010","unstructured":"Wierzbicka-Hainaut E, Sassolas B, Mourey L, Guillot B, Bedane C, Guillet G, Tourani JM (2010) Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. Melanoma res 20 (2): 141\u2013146","journal-title":"Melanoma res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T20:03:31Z","timestamp":1741205011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,24]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["BFbjc2011178"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.178","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,24]]}}}